IP Library Patent Application 13294346
Patent Application
App. No. 13/294,346

LOCALIZED THERAPY FOLLOWING BREAST CANCER SURGERY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/294,346
Abstract

Particles providing prolonged release of chemotherapy are injected or implanted into surgical sites in the breast following removal of cancerous tissue. In one embodiment, the particles are designed to not release formulation for approximately two to three weeks after surgery so as to not inhibit healing; in another embodiment particles are not administered until two to three weeks after surgery, and release immediately. The particles then release an effective amount of a chemotherapeutic such as a taxane to inhibit proliferation of any remaining cancer cells at or near the surgical site. This may also help prevent overproliferation leading to scarring with the surgical region.

Claims (10)

1 . A method for decreasing the reoccurrence of breast cancer in a patient who has been treated for breast cancer comprising administering at or near a site where breast cancer cells were removed particles releasing an effective amount of a chemotherapeutic to inhibit proliferation of any remaining cancer cells at or near the surgical site.

2 . The method of claim 1 wherein the particles release an effective amount of chemotherapeutic for a period of between six and twelve months.

3 . The method of claim 1 wherein the particles are administered at least ten days after surgery to remove the cancer cells.

4 . The method of claim 1 wherein the particles are administered following a negative diagnostic scan after surgery to remove the cancer cells.

5 . The method of claim 3 wherein the particles release an effective amount of chemotherapeutic to inhibit scarring or formation of fibrotic tissue.

6 . The method of claim 1 wherein the particles further comprising an imaging agent.

7 . The method of claim 6 wherein the particles are imaged after administration.

8 . The method of claim 1 wherein the chemotherapeutic is selected from the group consisting of cisplatin, BCNU, taxol and other taxanes, doxorubicin, anti-estrogens and anti-estrogen receptors.

9 . The method of claim 1 , wherein the patient is a woman.

10 . A microparticulate formulation for use in the method of claim 1 .

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Feb 28, 2025
From: THE BANK OF NOVA SCOTIA
To: SEAGATE TECHNOLOGY US HOLDINGS, INC.; EVAULT, INC. (F/K/A I365 INC.); SEAGATE TECHNOLOGY LLC
Reel/Frame 070363/0903 →
RELEASE OF SECURITY INTEREST Recorded Jul 23, 2024
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: SEAGATE TECHNOLOGY LLC; EVAULT INC
Reel/Frame 068457/0076 →
RELEASE OF SECURITY INTEREST Recorded May 20, 2024
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: SEAGATE TECHNOLOGY LLC; EVAULT, INC. (F/K/A I365 INC.); SEAGATE TECHNOLOGY US HOLDINGS, INC.
Reel/Frame 067471/0955 →
SECURITY AGREEMENT Recorded Oct 15, 2012
From: SEAGATE TECHNOLOGY LLC; EVAULT, INC. (F/K/A I365 INC.); SEAGATE TECHNOLOGY US HOLDINGS, INC.
To: THE BANK OF NOVA SCOTIA, AS ADMINISTRATIVE AGENT
Reel/Frame 029127/0527 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded Oct 15, 2012
From: SEAGATE TECHNOLOGY LLC; EVAULT, INC. (F/K/A I365 INC.); SEAGATE TECHNOLOGY US HOLDINGS, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 029253/0585 →